Saifullah Nasir, MD
Internal Medicine · Schaumburg, ILNPI 1427343938
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Novartis at 25.7% of the total. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Boehringer Ingelheim$1K
- Pfizer$958
- AstraZeneca$461
- E.r. Squibb & Sons, L.L.C.$428
- Johnson & Johnson$337
- plus $2K from 28 others
Across 150 payments — averaging $11,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$987K
- AbbVie$578K
- Boehringer Ingelheim International GmbH$45K
- Amgen$31K
- Boehringer Ingelheim Pharma GmbH & Co.kg$22K
- Ionis Pharmaceuticals, Inc.$19K
- plus $11K from 1 others
What the payments were for
- Speaking & faculty fees$170%
- Food & beverage$7,039100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 99 | $1,815 |
| Boehringer Ingelheim | 47 | $1,239 |
| Pfizer | 67 | $958 |
| AstraZeneca | 26 | $461 |
| E.r. Squibb & Sons, L.L.C. | 32 | $428 |
| Johnson & Johnson | 18 | $337 |
| Amgen | 10 | $257 |
| Esperion Therapeutics, Inc. | 12 | $253 |
| AbbVie(2 entities) | 10 | $222 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $180 |
| Novo Nordisk | 7 | $145 |
| Preventric Diagnostics, Inc. | 2 | $117 |
| Amarin Pharma, Inc. | 4 | $88 |
| Merck | 4 | $69 |
| Kestra Medical Technology Services, Inc. | 2 | $50 |
| Abbott | 2 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $40 |
| Infobionic, Inc | 1 | $39 |
| GSK | 2 | $38 |
| Cleerly, Inc. | 1 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Biotronik Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Medicure Pharma Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Medicomp Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $12 |
| Coala Life Inc | 1 | $10 |
| Bardy Diagnostics, Inc. | 2 | $8 |
How this compares
$7,070 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $437,403 |
| XareltoRivaroxaban | 104 | $152,447 |
| JardianceEmpagliflozin | 87 | $135,143 |
| EntrestoSacubitril/Valsartan | 63 | $91,905 |
| OzempicSemaglutide | 33 | $55,892 |
| FarxigaDapagliflozin Propanediol | 38 | $51,387 |
| JanuviaSitagliptin Phosphate | 13 | $19,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,566 |
| Metoprolol Succinate | 517 | $8,685 |
| Atorvastatin Calcium | 829 | $8,435 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,311 |
| Potassium Chloride | 216 | $4,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $4,393 |
| Lisinopril | 398 | $3,640 |
| Levothyroxine Sodium | 195 | $3,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $958 | $437,403311 claims |
| Johnson & JohnsonXarelto | $337 | $152,447104 claims |
| Boehringer IngelheimJardiance | $1,239 | $135,14387 claims |
| NovartisEntresto | $1,815 | $91,90563 claims |
| Novo NordiskOzempic | $145 | $55,89233 claims |
| AstraZenecaFarxiga | $461 | $51,38738 claims |
| MerckJanuvia | $69 | $19,58413 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $38 | $16,87728 claims |
| AbbVieSynthroid | $222 | $1,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Schaumburg
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
- Peter O DonnellChicago$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.